ASC Oncology GmbH

📍 Berlin, Germany🗓 Founded 2019👥 9 employees💰 Last funded Jun 2022
Biotechnology🌐 asc-oncology.com
Website LinkedIn
Reverse Clinical Engineering developed by ASC Oncology begins even before the start of chemotherapy: After the cancer is diagnosed, we use tumor tissue taken in a biopsy or from surgery to grow small copies of the tumor (so-called tumor organoids). We carry out tests on these organoids in the laboratory with various cancer drugs. We determine which drugs work particularly well (destruction of the organoids) and which do not work at all. Our results are a valuable aid to the attending physician when planning cancer therapy. In this way, a cancer drug or a combination of drugs can already be used with first line therapy, to benefit the patient as early as possible.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in ASC Oncology GmbH?
ASC Oncology GmbH has 1 investors on record on gritt.io, 1 mid-stage.
When did ASC Oncology GmbH last raise funding?
The most recent investment in ASC Oncology GmbH recorded on gritt.io was in June 2022.
When was ASC Oncology GmbH founded?
ASC Oncology GmbH was founded in 2019.
What industry is ASC Oncology GmbH in?
ASC Oncology GmbH operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is ASC Oncology GmbH based?
ASC Oncology GmbH is headquartered in Berlin, Germany.